7 stories mentioning ASX:PARUpdated 6d ago
Every FINWIRES story that references ASX:PAR, newest first.
Paradigm Biopharmaceuticals (ASX:PAR) appointed Daniel Furtner as its Chief Medical Officer, effective Wednesday, according to a Tuesday Australian bourse filing.Furtner succeeds Donna Skerrett, who will remain with the firm as a senior scientific advisor.Furtner previously served as the senior director of medical affairs for the Asia Pacific region at CSL.Its shares fell 2% in recent trading on Tuesday.
Paradigm Biopharmaceuticals (ASX:PAR) drew down the remaining balance of tranche 4, valued at $2 million, under its $27 million convertible note facility with Obsidian Global Partners, according to a Friday Australian bourse filing.Following the drawdown, about $5 million remains available under the facility, providing continued financial flexibility to support phase 3 execution and broader commercial readiness activities, the filing added.The company's shares plunged 13% in recent Friday trade.
Paradigm Biopharmaceuticals (ASX:PAR) said an independent Data Safety Monitoring Board recommended that the company's phase 3 clinical trial of a knee osteoarthritis treatment continue without modification, according to a Thursday filing with the Australian bourse.The trial is evaluating injectable pentosan polysulfate sodium in participants with knee osteoarthritis, with the change in pain intensity at day 112 set as the primary endpoint.The safety board issued the recommendation after completing a review of about 80% of the participants who have completed dosing, the company said.The trial's interim analysis remains on track for September.Paradigm Biopharmaceuticals shares gained 1% in recent Thursday trade.
Paradigm Biopharmaceuticals (ASX:PAR) completed the drawdown of the fourth tranche, valued at $3 million, under its $27 million convertible note facility with Obsidian Global Partners, according to a Monday Australian bourse filing.The drawdown provides additional working capital to support its global phase three clinical trial, evaluating the use of injectable pentosan polysulfate sodium to treat knee osteoarthritis. It completed participant enrolment into the study, with 538 participants randomized.After the drawdown, around $7 million remains available under the facility.Its shares rose 2% in recent trading on Monday.
Paradigm Biopharmaceuticals (ASX:PAR) completed enrollment in a phase 3 clinical trial to evaluate its Zilosul injectable pentosan polysulfate sodium for the treatment of pain linked to knee osteoarthritis, according to a Monday filing with the Australian bourse.The company said 538 participants have started treatment in the study, surpassing the original target of 466 participants.An interim analysis of the trial remains on track for September, while top-line results are due in the first quarter of 2027, the company said.Paradigm Biopharmaceuticals shares gained 7% in recent Monday trade.
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
Paradigm Biopharmaceuticals (ASX:PAR) completed a AU$14 million share placement to institutional and sophisticated investors, upsized from an initial target of AU$8 million due to high demand, according to a Monday filing with the Australian bourse.The company also launched a share purchase plan for eligible shareholders to generate up to an additional AU$2 million, per the filing.In the placement, the company issued about 73.7 million ordinary shares at a price of AU$0.19 each.The capital raising provides funding flexibility through the interim analysis, expected in the third quarter, of the company's phase three knee osteoarthritis trial.Shares of Paradigm Biopharmaceuticals fell nearly 16% in recent Monday trade.
